Inogen Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $303.6M+8.9% YoYTTM through 30 Jun 2026
Net Income -$24.6MTTM through 30 Jun 2026
Free Cash Flow -$5MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 44.2% |
| EBITDA Margin | -3.6% |
| Operating Margin | -8.7% |
| Net Margin | -8.1% |
Returns
-11.8%ROE
-7.6%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio3.12x
Net Debt-$120.9Mnet cash position
Cash & Equivalents$87.3M
Quality Metrics
Altman Z-Score1.06
Piotroski F-Score3 / 9
FCF Margin-1.6%
Rule of 4015.8
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $348.7M
Diluted EPS-$0.91TTMFY2025: $-0.86
Dividend
No dividend
Capital Allocation
R&D Spend$21.1M
Capex Intensity0.8%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| International Sales | $139.5M | +18.4% | View detailsRemains a key growth engine with strong demand for portable oxygen concentrators (POCs). |
| U.S. Sales | $156.9M | View detailsRepositioning sales channels for long-term competitiveness. | |
| U.S. Rentals | $52.3M | View detailsPressured by reimbursement mix and reduced patients on service. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.